Hypofractionated Accelerated Pelvic Nodal Radiotherapy for Prostate Cancer
This study is testing a new way to deliver radiation therapy (RT) called Hypofractionated Radiation Therapy for men with prostate cancer. This treatment uses proton therapy, delivered four days a week, to target the prostate and surrounding lymph nodes. The goal is to find a radiation schedule that is safe, meaning it causes less than 33% acute (short-term) side effects within 90 days of treatment completion. The study is open to men aged 18 and older who have been diagnosed with prostate adenocarcinoma within the last 180 days and have intermediate to high-risk prostate cancer requiring radiation to both the prostate and pelvic lymph nodes. The current status of this study is unclear.
- Study design
- This is an interventional study, not specifying a phase, aiming to enroll 18 participants. It is designed to test three different, shorter radiation schedules.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint is measured within 90 days of completing radiation therapy.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- HypoFx RT schedule that results in <33% acute dose-limiting toxicity with accelerated, HypoFx pelvic nodal RTWithin 90 days of completing RT
The frequency of all observed acute GI, GU, hematologic, and neurologic dose limiting toxicities by CTCAE v5 grade will be tabulated. DLT is defined as treatment-related: Grade ≥3 GI (small bowel or rectal) toxicity, Grade ≥3 GU toxicity, Grade ≥3 hematologic, Grade ≥3 neurologic toxicity, or any grade 5 treatment-related adverse events.